Grown Rogue International Inc banner
G

Grown Rogue International Inc
CNSX:GRIN

Watchlist Manager
Grown Rogue International Inc
CNSX:GRIN
Watchlist
Price: 0.53 CAD -11.67% Market Closed
Market Cap: CA$132.5m

EV/OCF

42
Current
128%
More Expensive
vs 3-y average of 18.4

Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.

EV/OCF
42
=
Enterprise Value
CA$129.6m
/
Operating Cash Flow
$2.3m

Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.

EV/OCF
42
=
Enterprise Value
CA$129.6m
/
Operating Cash Flow
$2.3m

Valuation Scenarios

Grown Rogue International Inc is trading above its 3-year average

If EV/OCF returns to its 3-Year Average (18.4), the stock would be worth CA$0.23 (56% downside from current price).

Statistics
Positive Scenarios
0/4
Maximum Downside
-81%
Maximum Upside
No Upside Scenarios
Average Downside
71%
Scenario EV/OCF Value Implied Price Upside/Downside
Current Multiple 42 CA$0.53
0%
3-Year Average 18.4 CA$0.23
-56%
5-Year Average 8.1 CA$0.1
-81%
Industry Average 10.4 CA$0.13
-75%
Country Average 11.9 CA$0.15
-72%

Forward EV/OCF
Today’s price vs future operating cash flow

Not enough data available to calculate forward EV/OCF

Peer Comparison

All Multiples
EV/OCF
P/E
All Countries
Close
Market Cap EV/OCF P/E
CA
Grown Rogue International Inc
CNSX:GRIN
132.3m CAD 42 15.1
US
Eli Lilly and Co
NYSE:LLY
835.2B USD 51.6 40.5
US
Johnson & Johnson
NYSE:JNJ
547.8B USD 23.4 26
CH
Roche Holding AG
SIX:ROG
248.4B CHF 15.2 20.1
UK
AstraZeneca PLC
LSE:AZN
216.4B GBP 21.1 28
CH
Novartis AG
SIX:NOVN
223.1B CHF 15.2 19.5
US
Merck & Co Inc
NYSE:MRK
276.9B USD 18.8 15.2
IE
Endo International PLC
LSE:0Y5F
244.4B USD 936 -83.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.1T DKK 10.5 11.4
US
Pfizer Inc
NYSE:PFE
153.5B USD 17.2 19.8
US
Bristol-Myers Squibb Co
NYSE:BMY
118.2B USD 10.6 16.8
P/E Multiple
Earnings Growth PEG
CA
G
Grown Rogue International Inc
CNSX:GRIN
Average P/E: 21.2
15.1
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
40.5
32%
1.3
US
Johnson & Johnson
NYSE:JNJ
26
8%
3.3
CH
Roche Holding AG
SIX:ROG
20.1
14%
1.4
UK
AstraZeneca PLC
LSE:AZN
28
25%
1.1
CH
Novartis AG
SIX:NOVN
19.5
14%
1.4
US
Merck & Co Inc
NYSE:MRK
15.2
14%
1.1
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -83.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
11.4
0%
N/A
US
Pfizer Inc
NYSE:PFE
19.8
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
16.8
16%
1

Market Distribution

Higher than 87% of companies in Canada
Percentile
87th
Based on 1 926 companies
87th percentile
42
Low
0 — 7.9
Typical Range
7.9 — 19.5
High
19.5 —
Distribution Statistics
Canada
Min 0
30th Percentile 7.9
Median 11.9
70th Percentile 19.5
Max 22 577.3

Grown Rogue International Inc
Glance View

Market Cap
132.5m CAD
Industry
Pharmaceuticals

Grown Rogue International, Inc. operates as a seed to experience cannabis brand. The company is headquartered in Toronto, Ontario. The company went IPO on 2016-11-18. The Company’s geographical segments include the United States and Canada. The firm is a vertically integrated cannabis brand that produces and distributes cannabis products. The firm's products include sungrown and indoor flowers, along with nitro-sealed indoor, and sungrown pre-rolls and jars.

GRIN Intrinsic Value
0.23 CAD
Overvaluation 56%
Intrinsic Value
Price CA$0.53
G
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett